Press releases
- Omeros Corporation Reports Fourth Quarter and Year-End 2023 Financial Results
- Omeros Corporation to Announce Fourth Quarter and Year-End Financial Results on April 1, 2024
- Omeros Corporation Announces Upcoming Presentation Detailing Narsoplimab Compassionate Use in Nine Patients with Hematopoietic Stem Cell Transplant-associated Thrombotic Microangiopathy
Key statistics
As of last trade, Omeros Corp (3O8:FRA) traded at 3.29, 236.75% above the 52 week low of 0.977 set on Oct 27, 2023.
52-week range
Short selling activityProvided by S&P Global Market Intelligence
Open | 3.34 |
---|---|
High | 3.34 |
Low | 3.29 |
Bid | 3.24 |
Offer | 3.31 |
Previous close | 3.35 |
Average volume | 26.67 |
---|---|
Shares outstanding | 57.94m |
Free float | 55.40m |
P/E (TTM) | -- |
Market cap | 210.92m USD |
EPS (TTM) | -2.79 USD |
Data delayed at least 15 minutes, as of May 08 2024 17:00 BST.
More ▼